Drug Trial Radar · NCT07387003
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
345
Planned (sponsor's estimate)
Start
Apr 10, 2026
Primary completion
Feb 11, 2027
Study completion Sep 23, 2027
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.
Conditions
- Type 2 Diabetes (T2DM)
Interventions
GZR101-80Drug
Administered SC
GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)Drug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin A1c (HbA1c) from baseline after 16 weeks of treatment.Time frame: Baseline , 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.